33 results about "Bispecific monoclonal antibody" patented technology

The invention relates to a medicine of a bispecific monoclonal antibody, and especially to a medicine of a bispecific monoclonal antibody to human vascular endothelial growth factor (VEGF/VEGF-A) and platelet-derived growth factor receptor (PDGFR) for resistance to angiogenesis of tumor. The bispecific antibody to VEGF/PDGFR beta provided in the invention is characterized in that: a monoclonal antibody to VEGF is used as the base for the antibody and a single chain antibody to PDGFR beta is connected with the terminal of FC segment of the monoclonal antibody to VEGF to form the bispecific antibody to VEGF/PDGFR beta. The bispecific antibody related to in the invention is obtained by employing technical means like gene engineering and constructing antibody segments which identify VEGF and PDGFR beta in a same antibody molecule that can be specifically bound with the two antibody segments; the effect of the bispecific antibody on inhibiting angiogenesis of tumor issue is obviously superior to that of a single antibody to VEGF; and the bispecific antibody has good activity in resisting tumors.

Disclosed are a CH3 domain variant pair of an antibody, a method for preparing same, and a use thereof. A mutation is induced in the CH3 domain so as to improve a yield of forming a heterodimer heavy chain constant region of an antibody. The CH3 domain heterodimer forms a heterodimer heavy chain constant region with a high efficiency of 90 to 95% or more and also has outstanding heat stability. A heterodimer heavy chain constant region including the CH3 domain heterodimer can construct a bispecific monoclonal antibody which simultaneously recognizes two kinds of antigens. The CH3 domain heterodimer and the bispecific antibody or fusion protein of an antibody constant region comprising same can be usefully applied to the treatment or prevention of a disease associated with a target antigen or a target protein.

The invention provides methods of purifying antibodies using various antibody-specific purification media to rapidly and efficiently separate mixtures of antibodies, antibody fragments and/or antibody components to isolate a desired antibody product from the mixture. The invention relates to the purification of bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, e.g., antibodies composed of a single heavy chain and two different light chains, one containing a Kappa constant domain and the other a Lambda constant domain, including antibodies of different specificities that share a common heavy chain. The invention also provides the methods of efficiently purifying intact antibodies by separating the intact antibody from non-intact antibodies including free light chains.

The invention relates to monoclonal and/or monovalent antibodies that bind CD47. The invention relates to monoclonal and/or monovalent antibodies that bind CD19. The invention also relates to novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD47. The invention also relates to novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD19.

The invention relates to a double-specificity monoclonal antibody medicament, in particular to an anti-vascular endothelial growth factor (VEGF/VEGF-A) and anti-platelet-derived growth factor receptor (PDGFR) double-specificity monoclonal antibody medicament for resisting tumor angiogenesis; and the anti-VEGF/PDGFR beta double-specificity antibody is characterized by being constructed by connecting an anti-PDGFR beta single-chain antibody at the tail end of an FC segment based on an anti-VEGF monoclonal antibody.

The invention discloses a double-specificity monoclonal antibody resistant to triazophos and chlorpyrifos and a preparation method and application thereof, and belongs to the technical field of biology. The double-specificity monoclonal antibody has specificity for triazophos and chlorpyrifos simultaneously. The preparation method for the monoclonal antibody comprises the steps as follows: synthesizing half antigens and artificial antigens of triazophos and chlorpyrifos; utilizing the artificial antigens of triazophos to prepare hybridoma cell strains secreting a component resistant to triazophos; utilizing the artificial antigens of chlorpyrifos to prepare hybridoma cell strains secreting a component resistant to chlorpyrifos; and after the triazophos-resistant hybridoma cell strains and hybridoma-resistant hybridoma cell strains are subjected to cell fusion, screening to obtain tetrasomic hybridoma cells which secrete the double-specificity monoclonal antibody resistant to triazophos and chlorpyrifos. The double-specificity monoclonal antibody prepared by the invention has the advantages that the characters are stable, the detection sensitivity is high, the double-specificity monoclonal antibody can be produced massively, and meanwhile the antibody is used for establishing an ELISA (enzyme-linked immuno sorbent assay) analysis method, so that the technical basis for the rapid detection of triazophos and chlorpyrifos is provided.

The invention discloses a bispecific monoclonal antibody resisting clenbuterol hydrochloride and olaquindox and a preparation method of the bispecific monoclonal antibody, belonging to the field of biotechnology. The bispecific monoclonal antibody has specificity to both the clenbuterol hydrochloride and the olaquindox. The bispecific monoclonal antibody acquired by the preparation method disclosed by the invention has the advantages of stable properties and high detection sensitivity, can be abundantly produced and provides the technological base for fast detection of the clenbuterol hydrochloride and the olaquindox.

The invention relates to a bispecific monoclonai antibody capable of simultaneously recognizing imidacloprid and parathion-methyl pesticides, and a preparation method thereof, belonging to the field of biological technology. The bispecific monoclonai antibody FQ-D6 which can be stably secreted and simultaneously resist imidacloprid and parathion-methyl pesticides is prepared by fusing hybridoma cell capable of secreting anti-parathion-methyl monoclonal antibody and an imidacloprid antigen-immunized rat splenocyte cell through a hydridizatio-hybridoma technique. Proved by effectiveness verification, the antibody can be used for fast and sensitively detecting residuals of the parathion-methyl and the imidacloprid in agricultural production environment and agricultural products. The preparation technology of the bispecific monoclonai antibody capable of simultaneously resisting imidacloprid and parathion-methyl pesticides is simple, convenient and feasible, the whole preparation process of the antibody is not required for special instruments and equipment, thereby being easy for factorization scale production.

The invention discloses a dual-specificity monoclonal antibody for resisting chloramphenicol and apramycin as well as a preparation method and application thereof, belonging to the technical field of biotechnology. The dual-specificity monoclonal antibody simultaneously has specificity for the chloramphenicol and the apramycin. The preparation method of the dual-specificity monoclonal antibody comprises the steps of: synthesizing haptens and artificial antigens of the chloramphenicol and the apramycin; preparing and secreting chloramphenicol resistance hybridoma cell strains by using the artificial antigens of the chloramphenicol; preparing and secreting apramycin resistance hybridoma cell strains by using artificial antigens of the apramycin; fusing the chloramphenicol resistance hybridoma cell strains and the apramycin resistance hybridoma cell strains, then screening to obtain tetrasomic hybridoma cells which secrete the dual-specificity monoclonal antibody for resisting chloramphenicol and apramycin. The dual-specificity monoclonal antibody obtained by the method has stable character and high detection sensitivity and can be produced in large quantities; and an ELISA (Enzyme Linked Immunosorbent Assay) analytical method is established by using the antibody and provides technological base for rapid detection of the chloramphenicol and apramycin.

The plant-based production of a therapeutic antibody against West Nile Virus is disclosed.

The invention discloses an immunoaffinity column based on a bispecific monoclonal antibody for aflatoxin B1 and ochratoxin A and application of the immunoaffinity column, and specifically discloses a preparation method of the bispecific monoclonal antibody for aflatoxin B1 (AFB1) and ochratoxin A (OTA). According to the invention, a hybridoma cell capable of stably secreting an antibody capable of simultaneously recognizing both AFB1 and OTA is obtained, and the prepared bispecific monoclonal antibody can be used in the preparation of an immunoaffinity column. The affinity column can simultaneously extract two objects AFB1 and OTA only by coupling one antibody, coupling rate is easy to adjust and measure, number of binding sites of the two objects is equal, structure is uniform, and interference is less. The immunoaffinity column disclosed by the invention can be used in combination with ELISA, has characteristics of simplicity, convenience, rapidness, strong specificity and relatively high sensitivity, and has important application value in detecting and monitoring AFB1 and OTA multi-residues in food and agricultural products.

The invention relates to bivalent bispecific monoclonal antibodies (bbmAb) or variants thereof for use in the treatment or for use in alleviating the symptoms of an NLRC4 inflammasomopathy, such as an NLRC4-GOF inflammasomopathy in a subject in need thereof. This invention also relates to bivalent bispecific monoclonal antibodies (bbmAb) or variants thereof for use in the treatment or for use in alleviating the symptoms of AIFEC in a subject in need thereof.